NCT05828069 · Interventional trial
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Overall registry status Recruiting
Phase 2
Conditions Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Delaware Valley sites
- Children's Hospital of Philadelphia · Philadelphia, PA · Philadelphia County · Recruiting
- Saint Christopher's Hospital for Children · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory